MX2023011856A - Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. - Google Patents
Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.Info
- Publication number
- MX2023011856A MX2023011856A MX2023011856A MX2023011856A MX2023011856A MX 2023011856 A MX2023011856 A MX 2023011856A MX 2023011856 A MX2023011856 A MX 2023011856A MX 2023011856 A MX2023011856 A MX 2023011856A MX 2023011856 A MX2023011856 A MX 2023011856A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- combination therapies
- prmt5 inhibitors
- inhibitors
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 101150097768 prmt5 gene Proteins 0.000 title 1
- 102100030708 GTPase KRas Human genes 0.000 abstract 1
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 abstract 1
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172639P | 2021-04-08 | 2021-04-08 | |
| US202163252998P | 2021-10-06 | 2021-10-06 | |
| PCT/US2022/023394 WO2022216648A1 (en) | 2021-04-08 | 2022-04-05 | Combination therapies using prmt5 inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023011856A true MX2023011856A (es) | 2024-01-08 |
Family
ID=81748231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023011856A MX2023011856A (es) | 2021-04-08 | 2022-04-05 | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12128048B2 (https=) |
| EP (1) | EP4319754A1 (https=) |
| JP (1) | JP2024513492A (https=) |
| KR (1) | KR20230167053A (https=) |
| AU (1) | AU2022253455A1 (https=) |
| CA (1) | CA3214530A1 (https=) |
| IL (1) | IL307392A (https=) |
| MX (1) | MX2023011856A (https=) |
| WO (1) | WO2022216648A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500385A (ja) * | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| EA202190749A1 (ru) * | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| US20240208912A1 (en) * | 2021-03-11 | 2024-06-27 | Mirati Therapeutics, Inc. | MTA-Cooperative PRMT5 Inhibitors |
| WO2023098439A1 (zh) * | 2021-11-30 | 2023-06-08 | 上海和誉生物医药科技有限公司 | 一种吡唑衍生物，其制备方法和在药学上的应用 |
| WO2023125540A1 (zh) * | 2021-12-27 | 2023-07-06 | 南京明德新药研发有限公司 | 吡唑-1(2h)-酞嗪酮类化合物及其应用 |
| WO2023202626A1 (zh) * | 2022-04-22 | 2023-10-26 | 北京望实智慧科技有限公司 | 稠和哒嗪酮化合物作为prmt5抑制剂 |
| CN119301101A (zh) * | 2022-07-29 | 2025-01-10 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
| WO2024027703A1 (zh) * | 2022-08-02 | 2024-02-08 | 上海艾力斯医药科技股份有限公司 | 一种prmt5抑制剂、其制备方法及应用 |
| CN120265615A (zh) * | 2022-11-29 | 2025-07-04 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪的化合物 |
| JP2026506429A (ja) * | 2022-12-21 | 2026-02-25 | アムジエン・インコーポレーテツド | Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療 |
| CN120712260A (zh) * | 2023-02-21 | 2025-09-26 | 正大天晴药业集团股份有限公司 | 含有二氢酞嗪和烯基的化合物及其用途 |
| WO2025157289A1 (zh) * | 2024-01-26 | 2025-07-31 | 上海湃隆生物科技有限公司 | 包含prmt5抑制剂和krasg12c抑制剂的药物组合物 |
| WO2025217015A1 (en) * | 2024-04-08 | 2025-10-16 | Mirati Therapeutics, Inc. | Combination therapies using prmt5 inhibitors and kras g12d inhibitors for the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102444509B1 (ko) | 2016-05-18 | 2022-09-19 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제 |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| JP2021176819A (ja) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| ES2961253T3 (es) | 2018-08-31 | 2024-03-11 | Mirati Therapeutics Inc | Inhibidores de KRas G12C |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| IL290341B2 (en) | 2019-09-12 | 2024-11-01 | Mirati Therapeutics Inc | Mta-cooperative prmt5 inhibitors |
| KR20220086628A (ko) | 2019-10-22 | 2022-06-23 | 루핀 리미티드 | Prmt5 저해제의 약학적 조합물 |
-
2022
- 2022-04-05 WO PCT/US2022/023394 patent/WO2022216648A1/en not_active Ceased
- 2022-04-05 MX MX2023011856A patent/MX2023011856A/es unknown
- 2022-04-05 JP JP2023561858A patent/JP2024513492A/ja active Pending
- 2022-04-05 AU AU2022253455A patent/AU2022253455A1/en active Pending
- 2022-04-05 IL IL307392A patent/IL307392A/en unknown
- 2022-04-05 KR KR1020237036495A patent/KR20230167053A/ko active Pending
- 2022-04-05 EP EP22724162.7A patent/EP4319754A1/en active Pending
- 2022-04-05 US US17/713,472 patent/US12128048B2/en active Active
- 2022-04-05 CA CA3214530A patent/CA3214530A1/en active Pending
-
2024
- 2024-09-05 US US18/825,566 patent/US20240423987A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240423987A1 (en) | 2024-12-26 |
| US20220331324A1 (en) | 2022-10-20 |
| JP2024513492A (ja) | 2024-03-25 |
| KR20230167053A (ko) | 2023-12-07 |
| IL307392A (en) | 2023-12-01 |
| WO2022216648A1 (en) | 2022-10-13 |
| US12128048B2 (en) | 2024-10-29 |
| AU2022253455A1 (en) | 2023-11-02 |
| CA3214530A1 (en) | 2022-10-13 |
| EP4319754A1 (en) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023011856A (es) | Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer. | |
| MX2023010430A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). | |
| MX2025001648A (es) | Inhibidores del oncogen homologo del virus de sarcoma de rata kirsten (kras) | |
| MX2023010429A (es) | Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras). | |
| MX2025015502A (es) | Inhibidores del oncogén de sarcoma de rata de kirsten (kras) | |
| MX2024009727A (es) | Terapias de combinacion. | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2024005228A (es) | Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras). | |
| PH12022551013A1 (en) | Pyridazinones as parp7 inhibitors | |
| PH12020551923A1 (en) | Methods and compositions for treating cancer | |
| MX2023008193A (es) | Procedimientos para tratar el cáncer. | |
| EA201490814A1 (ru) | Лечение злокачественной опухоли ингибиторами tor-киназы | |
| WO2019169065A3 (en) | Wee1 kinase inhibitors and methods of treating cancer using the same | |
| MX2018000216A (es) | Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos. | |
| MX2022010977A (es) | Inhibidores de egfr, kras, braf y otros objetivos y uso de los mismos. | |
| MX2022010975A (es) | Inhibidores de egfr, kras, braf y otras dianas y uso de estos. | |
| MX2023010882A (es) | Compuestos y composiciones para el tratamiento de trastornos hematológicos. | |
| MX2017010595A (es) | Métodos, composiciones, y equipos para tratamiento de cáncer. | |
| MX2022000310A (es) | Inhibidores de proteina bcl-2. | |
| ZA201607488B (en) | Compounds for treating brain cancer | |
| AU2016246521A8 (en) | Treatment of lung cancer with inhibitors of glutaminase | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| PH12020552059A1 (en) | Dosing regimen for the treatment of pi3k related disorders | |
| MX2023004342A (es) | Politerapia de antagonistas de union al eje de pd-1 e inhibidores de lrrk2. | |
| MX2024013787A (es) | Inhibidores de menina-mll para el tratamiento de cáncer. |